Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candonilimab + all-trans retinoic acid
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Candonilimab + all-trans retinoic acid is an experimental combination therapy consisting of candonilimab, a tetravalent bispecific monoclonal antibody targeting both PD-1 and CTLA-4 immune checkpoints, and all-trans retinoic acid (ATRA), a small molecule derivative of vitamin A. Candonilimab works by simultaneously blocking the PD-1 and CTLA-4 pathways on T cells, thereby enhancing anti-tumor immune responses while reducing toxicity compared to traditional dual checkpoint blockade[1][5][6]. All-trans retinoic acid induces differentiation in certain cancer cells (notably in acute promyelocytic leukemia) and modulates gene expression through activation of nuclear retinoic acid receptors. The combination is being explored for synergistic effects in cancer immunotherapy, leveraging both enhanced T cell activation from checkpoint inhibition and potential tumor cell differentiation or immunomodulation from ATRA.
- Brand names
- Kaitani
- Other names
- CadonilimabTretinoinAK104 + ATRA
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on candonilimab + all-trans retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candonilimab + all-trans retinoic acid.